Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311332279> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4311332279 endingPage "S180" @default.
- W4311332279 startingPage "S180" @default.
- W4311332279 abstract "COVID-19 led to a global pandemic in 2020. Vaccines were developed with price points based on health policies defined under state of emergency declarations. As countries lift their state of emergency, price points may adopt a value-based approach. The aim of this research was to identify cost-effectiveness metrics expected to guide value-based negotiations for upcoming COVID-19 vaccines. A systematic search in PubMed was conducted to identify peer-reviewed cost-effectiveness evaluations on COVID-19 vaccines published since January 2020. Literature that met eligibility criteria was reviewed to identify clinical, health outcome, and economic metrics, price points, and ICER-sensitive metrics related to cost-effectiveness evaluations. A total of 331 articles were identified and screened. Of these, 21 cost-effectiveness evaluations were reviewed for the research. The most common health outcome metric was QALY (n=12). The most common clinical metrics were mortality (n=12) and ICU admission rate (n=12). The most common economic metrics were drug acquisition cost (n=15), hospital admission cost (n=11), and vaccine administration costs (n=10). The vaccination cost per dose ranged from $3.7-$47.0 USD (adjusted by purchasing power parity), with mRNA-based vaccines showing the highest price points. The most common factors driving ICER values were drug acquisition cost (n=4), vaccine efficacy (n=3), rate of vaccination (n=3), infection rate (n=3), and hospitalization cost (n=2). Willingness-to-pay (WTP) thresholds globally ranged from $9,000-$150,000 per QALY and were defined based on HTA agency guidelines, WHO recommendation, international reference, or published literature. As the global health crisis subsides, policy-makers may adopt alternative pricing approaches for COVID-19 vaccines. Considering the value-based pricing approach, optimizing cost-effectiveness strategies becomes critical. As part of these strategies, clinical trials should be designed to capture the most relevant cost-effectiveness metrics. Moreover, both price-sensitive parameters and national HTA and international WTP recommendations should be considered when assessing potential price points within the cost-effectiveness models." @default.
- W4311332279 created "2022-12-25" @default.
- W4311332279 creator A5034555698 @default.
- W4311332279 creator A5045501728 @default.
- W4311332279 creator A5053444555 @default.
- W4311332279 creator A5054513416 @default.
- W4311332279 date "2022-12-01" @default.
- W4311332279 modified "2023-09-27" @default.
- W4311332279 title "EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market" @default.
- W4311332279 doi "https://doi.org/10.1016/j.jval.2022.09.871" @default.
- W4311332279 hasPublicationYear "2022" @default.
- W4311332279 type Work @default.
- W4311332279 citedByCount "0" @default.
- W4311332279 crossrefType "journal-article" @default.
- W4311332279 hasAuthorship W4311332279A5034555698 @default.
- W4311332279 hasAuthorship W4311332279A5045501728 @default.
- W4311332279 hasAuthorship W4311332279A5053444555 @default.
- W4311332279 hasAuthorship W4311332279A5054513416 @default.
- W4311332279 hasBestOaLocation W43113322792 @default.
- W4311332279 hasConcept C112930515 @default.
- W4311332279 hasConcept C142724271 @default.
- W4311332279 hasConcept C144133560 @default.
- W4311332279 hasConcept C159047783 @default.
- W4311332279 hasConcept C160735492 @default.
- W4311332279 hasConcept C162118730 @default.
- W4311332279 hasConcept C162324750 @default.
- W4311332279 hasConcept C22070199 @default.
- W4311332279 hasConcept C2776125615 @default.
- W4311332279 hasConcept C3019080777 @default.
- W4311332279 hasConcept C50522688 @default.
- W4311332279 hasConcept C71924100 @default.
- W4311332279 hasConceptScore W4311332279C112930515 @default.
- W4311332279 hasConceptScore W4311332279C142724271 @default.
- W4311332279 hasConceptScore W4311332279C144133560 @default.
- W4311332279 hasConceptScore W4311332279C159047783 @default.
- W4311332279 hasConceptScore W4311332279C160735492 @default.
- W4311332279 hasConceptScore W4311332279C162118730 @default.
- W4311332279 hasConceptScore W4311332279C162324750 @default.
- W4311332279 hasConceptScore W4311332279C22070199 @default.
- W4311332279 hasConceptScore W4311332279C2776125615 @default.
- W4311332279 hasConceptScore W4311332279C3019080777 @default.
- W4311332279 hasConceptScore W4311332279C50522688 @default.
- W4311332279 hasConceptScore W4311332279C71924100 @default.
- W4311332279 hasIssue "12" @default.
- W4311332279 hasLocation W43113322791 @default.
- W4311332279 hasLocation W43113322792 @default.
- W4311332279 hasOpenAccess W4311332279 @default.
- W4311332279 hasPrimaryLocation W43113322791 @default.
- W4311332279 hasRelatedWork W1849751932 @default.
- W4311332279 hasRelatedWork W1997992770 @default.
- W4311332279 hasRelatedWork W2005688880 @default.
- W4311332279 hasRelatedWork W2152471158 @default.
- W4311332279 hasRelatedWork W2171323360 @default.
- W4311332279 hasRelatedWork W2902990771 @default.
- W4311332279 hasRelatedWork W2966232267 @default.
- W4311332279 hasRelatedWork W3090339921 @default.
- W4311332279 hasRelatedWork W32982267 @default.
- W4311332279 hasRelatedWork W4379799236 @default.
- W4311332279 hasVolume "25" @default.
- W4311332279 isParatext "false" @default.
- W4311332279 isRetracted "false" @default.
- W4311332279 workType "article" @default.